Diverse Biotech Inc, a United States-based biopharmaceutical company, has named Stella Vnook as its new chief executive officer, it was reported yesterday.
Vnook has more than 25 years' experience. She has most recently held senior leadership roles at Assertio Pharma, Jazz Pharmaceuticals, Catalent and Merck. She started her career in Research and Development in the Emergency Department at Temple University Hospital and later continued that work with oncology specialty interest at Temple/Fox Chase Cancer Centre as a pharmacist. Throughout her career she has developed extensive knowledge in many different therapy categories with a particular emphasis on Oncology, Pain Management and Cardiovascular Diseases.
William Fisher, Diverse Biotech's board chairman, said, 'Diverse Biotech is very excited to bring Stella on board as an experienced, knowledgeable, and innovative Senior Leader. Stella will work hand in hand with the current Diverse Biotech Board to continue to build a world class, innovative, experienced Executive Team.'
Cognision partners with Kynexis for use of COGNISION system in schizophrenia trial
CHMP issues positive opinion for DAWNZERA in hereditary angioedema
Merck to acquire Cidara Therapeutics in USD9.2bn deal to expand antiviral portfolio
EirGenix signs second global exclusive licensing deal with Sandoz
Longeveron secures US patent for stem cell therapy targeting aging-related frailty
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
Alkermes reports positive Phase 2 results for alixorexton in narcolepsy type 2